Jump to content

Charles Antzelevitch

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by RscprinterBot (talk | contribs) at 19:41, 7 April 2016 (Removing article categories and/or interwiki links on non-articles (Why?) (T4)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Charles Antzelevitch
Alma materUpstate Medical Center, SUNY at Syracuse (PhD)
Queens College, City University of New York (BA)
AwardsNorth American Society of Pacing and Electrophysiology (currently Heart Rhythm Society) Distinguished Scientist Award (2002)
American Heart Association Northeast Affiliate (currently Founders Affiliate[55]) Excellence in Cardiovascular Science Award (2003)
American Physiological Society Carl J. Wiggers Award (2007)
American College of Cardiology Distinguished Scientist Award (2011)
Cardiac Electrophysiology Society Distinguished Service Award (2015)
Scientific career
FieldsCardiology, Electrophysiology, Pharmacology, Genetics
InstitutionsLankenau Institute for Medical Research
Masonic Medical Research Laboratory

Charles Antzelevitch, PhD, is an American cardiovascular research scientist internationally known for his work in cardiac electrophysiology and arrhythmia syndromes. Currently, he is professor and executive director of cardiovascular research at Lankenau Institute for Medical Research (LIMR), a biomedical research facility in Wynnewood, Pennsylvania, and director of research at Lankenau Heart Institute, both part of Main Line Health.[1]

Dr. Antzelevitch was president of the Cardiac Electrophysiology Society from 1996 to 1998[2] and has served as secretary/treasurer since 1998.[3] He is an associate editor of Heart Rhythm,[4] the official journal of the Heart Rhythm Society[5] and the Cardiac Electrophysiology Society,[6] and serves on the editorial board of several other peer-reviewed medical publications, including Journal of Electrocardiology[7]and Journal of the American College of Cardiology.[8]

Education and Career

Dr. Antzelevitch graduated from Queens College, City University of New York with a BA in biology. He earned a PhD in pharmacology from State University of New York (SUNY) Upstate Medical University in 1978.[1] From 1977 to 1980, he held a postdoctoral fellowship in the department of experimental cardiology at the Masonic Medical Research Laboratory (MMRL) in Utica, New York.[9] [10] After his fellowship, he joined the staff at MMRL as a research scientist, where he continued his scientific work until 2015. [11] While at MMRL, Dr. Antzelevitch was named executive director and director of research (1984)[10] and became Gordon K. Moe Scholar, an endowed chair in experimental cardiology (1987).[9]

He was a member of the faculty at SUNY Health Science Center in Syracuse, New York, from 1980 until 2015. In 1980, he received an appointment as assistant professor in the department of pharmacology. He was later promoted to associate professor (1983), research professor (1986), and professor (1995) of pharmacology.[9] [10] [12]

In 2015, Dr. Antzelevitch became professor and executive director of cardiovascular research at LIMR and director of research at Lankenau Heart Institute.[11]

Research

Dr. Antzelevitch wrote his doctoral thesis in 1977 on the cardiac actions of quinidine.[13] After joining MMRL, he began investigating and publishing scholarly articles on the mechanisms underlying ventricular arrhythmias, including parasystole and reentry.[14] [15][16] Later, his interests expanded to include the genetic origins of inherited arrhythmia syndromes such as long QT,[17][18] short QT,[19] Brugada,[20][21] and early repolarization syndromes,[22][23] as well as the development of potential new treatments for atrial fibrillation (AF).[24][25][26] These investigations continue to be a focus of his current research at LIMR.[11]

In the 2010s, Dr. Antzelevitch began an ongoing investigation into genetic risk factors linked with the occurrence of life-threatening arrhythmias following myocardial infarction.[27] Additionally, with cardiac researcher Jose Di Diego, MD, Antzelevitch is exploring the heart-related therapeutic applications of human induced pluripotent stem cells and progenitor cells, including a possible role in the engineering of bioartificial hearts suitable for heart transplantation.[28][29] The first step in the organ bioengineering process is decellularization of cadaver hearts using detergents such as sodium dodecyl sulfate, leaving a collagen framework.[30] This bioartificial organ platform is termed a “ghost heart” because of its opaque white appearance. Induced pluripotent stem cells or progenitor cells generated from a patient’s skin, blood, bone marrow or other sources will then be used in an attempt to repopulate the organ and to form a fully functioning human heart.

Scientific achievements

Scientific discoveries Dr. Antzelevitch’s body of research has expanded scientific understanding of the heart’s electrical system in a number of ways. His work has been instrumental in identifying the cellular and ionic basis for the various waves that make up the electrocardiogram (ECG), including the J wave, T wave and U wave.[31][32][33] He and his research team helped to identify reflected reentry, late phase 3 early afterdepolarizations, and phase 2 reentry (electrical dysfunctions that promote extra heart beats) as potential trigger mechanisms for dangerous tachycardia and fibrillation.[14][25][34]

His research team pioneered work demonstrating electrical heterogeneity within ventricular myocardium, showing that cells in the epicardium and endocardium differ with respect to electrical properties and response to pharmacologic agents.[35][36] In 1990, his team at MMRL, including Serge Sicouri, MD, discovered the M cell, a unique type of heart cell in the deep layers of the ventricular myocardium. The researchers observed that the M cell has different electrical properties from other heart cells, responds differently to drugs that affect the heart, and may be associated with potentially dangerous wave formations on ECGs.[37][38]

In 2000, Dr. Antzelevitch and colleagues reported experimental findings challenging the belief that early repolarization (an ECG variant often seen in athletes) is always a benign condition by demonstrating that early repolarization is linked to the development of arrhythmias leading to sudden cardiac death in experimental modules.[39][40] Validation of this hypothesis came 8 years later in clinical studies from leading centers around the world.[41][42][43][44]

With cardiac researcher Gan-Xin Yan, MD, PhD, Dr. Antzelevitch used coronary-perfused wedge preparation technology[45] to develop a research model that helped pinpoint the cellular, ionic and genetic mechanisms underlying inherited arrhythmia syndromes such as long QT,[17] short QT,[19] Brugada,[20][46] and early repolarization[22][23] syndromes. With his research team, Antzelevitch has discovered 10 of the 18 genes found to be associated with Brugada syndrome and 5 of the 7 genes associated with early repolarization syndrome. In 2000, his research team, along with international colleagues, described a possible genetic link between long QT syndrome and sudden infant death syndrome.[47]

Contributions to clinical practice Dr. Antzelevitch’s research has helped to establish diagnostic criteria and treatment approaches for both inherited and acquired arrhythmia syndromes. With his colleagues, he demonstrated that quinidine could be used to treat ventricular tachycardia in experimental models of Brugada syndrome.[38][48] In 2000, Antzelevitch participated in the first Brugada syndrome consensus conference, which culminated in the report of diagnostic criteria for the inherited syndrome.[49] In 2005, he organized and was the lead co-author of the second Brugada syndrome consensus conference report, which elaborated on diagnostic criteria and addressed risk stratification and treatment approaches.[50] In April 2015, Dr. Antzelevitch and LIMR colleague Dr. Yan convened a consensus conference to update the scientific and clinical communities on the mechanisms, diagnosis, prognosis, risk stratification, and treatment of Brugada syndrome and other early repolarization syndromes, collectively known as J wave syndromes; the report of the J Wave Expert Consensus Conference is currently unpublished.[51]

In the realm of acquired arrhythmias, Dr. Antzelevitch’s research team was the first to recognize that the antianginal drug ranolazine blocks the electrical pathway in the heart known as the late sodium channel, an atrial-selective action that has potential benefit in the treatment of AF.[52] With cardiac electrophysiologist Alexander Burashnikov, PhD, Dr. Antzelevitch subsequently hypothesized and then demonstrated that combining ranolazine with dronedarone, a drug with a similar action but different mechanism, can significantly suppress the occurrence of AF.[26][53]

Publications

Dr. Antzelevitch has published 6 reference texts, more than 500 original peer-reviewed journal articles and book chapters, and over 370 abstracts.[11]

Selected peer-reviewed publications

Below are the top 20 most-cited journal articles authored or co-authored by Dr. Antzelevitch, according to Google Scholar:[54]

Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young BJ; American Heart Association; Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; Council on Epidemiology and Prevention (2006). “Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention”. Circulation 113 (14): 1807–1816. doi: 10.1161/circulationaha.106.174287. PMID 16567565.

Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, Gussak I, LeMarec H, Nademanee K, Perez Riera AR, Shimizu W, Schulze-Bahr E, Tan H, Wilde A (2005). “Brugada syndrome: report of the second consensus conference. Endorsed by the Heart Rhythm Society and the European Heart Rhythm Association”. Circulation 111 (5): 659–670. doi: 10.1161/01.cir.0000152479.54298.51. PMID 15655131.

Chen Q, Kirsch GE, Zhang D, Brugada R, Brugada J, Brugada P, Potenza D, Moya A, Borggrefe M, Breithardt G, Ortiz-Lopez R, Wang Z, Antzelevitch C, O’Brien RE, Schulze-Bahr E, Keating MT, Towbin JA, Wang Q (1998). “Genetic basis and molecular mechanism for idiopathic ventricular fibrillation”. Nature 392 (6673): 293–296. doi: 10.1038/32675. PMID 9521325.

Yan GX, Antzelevitch C (1999). “Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation”. Circulation 100 (15): 1660–1666. doi: 10.1161/01.cir.100.15.1660. PMID 10517739.

Yan GX, Antzelevitch C (1998). “Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome”. Circulation 98 (18): 1928–1936. doi: 10.1161/01.cir.98.18.1928. PMID 9799215.

Yan GX, Antzelevitch C (1996). “Cellular basis for the electrocardiographic J wave”. Circulation 93 (2): 372–379. doi: 10.1161/01.cir.93.2.372. PMID 8548912.

Antzelevitch C, Sicouri S, Litovsky SH, Lukas A, Krishnan SC, Di Diego JM, Gintant GA, Liu DW (1991). “Heterogeneity within the ventricular wall. Electrophysiology and pharmacology of epicardial, endocardial, and M cells”. Circ Res 69 (6): 1427–1449. doi: 10.1161/01.res.69.6.1427. PMID 1659499.

Wilde AA, Antzelevitch C, Borggrefe M, Brugada J, Brugada R, Brugada P, Corrado D, Hauer RN, Kass RS, Nademanee K, Priori SG, Towbin JA; Study Group on the Molecular Basis of Arrythmias of the European Society of Cardiology (2002). “Proposed diagnostic criteria for the Brugada syndrome: consensus report.” Circulation 106 (19): 2514–2519. doi: 10.1161/01.cir.0000034169.45752.4a. PMID 12417552.

Brugada R, Brugada J, Antzelevitch C, Kirsch GE, Potenza D, Towbin JA, Brugada P (2000). “Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts”. Circulation 101 (5): 510–515. doi: 10.1161/01.cir.101.5.510. PMID 10662748.

Brugada R, Hong K, Dumaine R, Cordeiro J, Gaita F, Borggrefe M, Menendez TM, Brugada J, Pollevick GD, Wolpert C, Burashnikov E, Matsuo K, Wu YS, Guerchicoff A, Bianchi F, Giustetto C, Schimpf R, Brugada P, Antzelevitch C (2004). “Sudden death associated with short-QT syndrome linked to mutations in HERG”. Circulation 109 (1): 30–35. doi: 10.1161/01.cir.0000109482.92774.3a. PMID 14676148.

Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, Escande D, Franz M, Malik M, Moss A, Shah R (2000). “The potential for QT prolongation and pro-arrhythmia by non–anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology”. Cardiovasc Res 47 (2): 219–233. doi: 10.1016/s0008-6363(00)00119-x. PMID 10947683.

Brugada J, Brugada R, Antzelevitch C, Towbin J, Nademanee K, Brugada P (2002). “Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3”. Circulation 105 (1): 73–78. doi: 10.1161/hc0102.101354. PMID 11772879.

Antzelevitch C, Pollevick GD, Cordeiro JM, Casis O, Sanguinetti MC, Aizawa Y, Guerchicoff A, Pfeiffer R, Oliva A, Wollnik B, Gelber P, Bonaros EP Jr, Burashnikov E, Wu Y, Sargent JD, Schickel S, Oberheiden R, Bhatia A, Hsu LF, Haissaguerre M, Schimpf R, Borggrefe M, Wolpert C (2007). “Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death”. Circulation 115 (4): 442–449. doi: 10.1161/circulationaha.106.668392. PMC 1952683. PMID 17224476.

Liu DW, Antzelevitch C (1995). “Characteristics of the delayed rectifier current (IKr and IKs) in canine ventricular epicardial, midmyocardial, and endocardial myocytes. A weaker IKs contributes to the longer action potential of the M cell”. Circ Res 76 (3): 351–365. doi: 10.1161/01.res.76.3.351. PMID 7859382.

Gussak I, Antzelevitch C, Bjerregaard P, Towbin JA, Chaitman BR (1999). “The Brugada syndrome: clinical, electrophysiologic and genetic aspects”. J Am Coll Cardiol 33 (1): 5–15. doi: 10.1016/s0735-1097(98)00528-2. PMID 9935001.

Sicouri S, Antzelevitch C (1991). “A subpopulation of cells with unique electrophysiological properties in the deep subepicardium of the canine ventricle. The M cell”. Circ Res 68 (6): 1729–1741. doi: 10.1161/01.res.68.6.1729. PMID 2036721.

Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM, Thomas G (2004). “Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties”. Circulation 110 (8): 904–910. doi: 10.1161/01.cir.0000139333.83620.5d. PMC 1513623. PMID 15302796.

Antzelevitch C, Shimizu W, Yan GX, Sicouri S, Weissenburger J, Nesterenko VV, Burashnikov A, Di Diego J, Saffitz J, Thomas GP (1999). “The M Cell: its contribution to the ECG and to normal and abnormal electrical function of the heart”. J Cardiovasc Electrophysiol 10 (8): 1124–1152. doi: 10.1111/j.1540-8167.1999.tb00287.x. PMID 10466495.

Antzelevitch C, Sicouri S (1994). “Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and torsade de pointes”. J Am Coll Cardiol 23 (1): 259–277. doi: 10.1016/0735-1097(94)90529-0. PMID 8277090.

Dumaine R, Towbin JA, Brugada P, Vatta M, Nesterenko DV, Nesterenko VV, Brugada J, Brugada R, Antzelevitch C (1999). “Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent”. Circ Res 85 (9): 803–809. doi: 10.1161/01.res.85.9.803. PMID 10532948.

Reference texts

Antzelevitch C, Brugada P, Brugada J, Brugada R, Nademanee K, Towbin J (1999). The Brugada Syndrome. Armonk (NY): Futura. (Camm AJ, editor. Clinical approaches to tachyarrhythmias; vol. 10). ISBN 0879934344.

Gussak I, Antzelevitch C, editors (2003). Cardiac Repolarization: Bridging Basic and Clinical Science. Totowa (NJ): Humana. (Contemporary cardiology). ISBN 1588290697.

Antzelevitch C, editor (2005). The Brugada Syndrome: From Bench to Bedside. Malden (MA): Blackwell Futura. ISBN 1405127783.

Gussak I, Antzelevitch C, editors (2008). Electrical Diseases of the Heart: Genetics, Mechanisms, Treatment, Prevention. London: Springer. ISBN 1846288533.

Antzelevitch C, guest editor (2011). Basic Science for the Clinical Electrophysiologist. Philadelphia: Saunders. (Cardiac electrophysiology clinics; vol. 3, no 1). ISBN 1455704237.

Gussak I, Antzelevitch C, editors (2013). Electrical Diseases of the Heart. 2nd ed. London: Springer. 2 vol. ISBN 9781447148807 (vol. 1); 9781447149774 (vol. 2).

Honors

  • 2002 – Distinguished Scientist Award, North American Society of Pacing and Electrophysiology (currently Heart Rhythm Society)
  • 2003 – Excellence in Cardiovascular Science Award, American Heart Association Northeast Affiliate (currently Founders Affiliate)[55]
  • 2007 – Carl J. Wiggers Award, American Physiological Society
  • 2011 – Distinguished Scientist Award, American College of Cardiology
  • 2015 – Distinguished Service Award, Cardiac Electrophysiology Society, Boston, Massachusetts

References

  1. ^ a b http://www.limr.org/lmr/Page.asp?PageID=LMR000327
  2. ^ http://cardiaceps.org/past-ces-presidents
  3. ^ http://cardiaceps.org/about-cardiaceps/
  4. ^ http://www.heartrhythmjournal.com/content/edboard
  5. ^ http://www.hrsonline.org
  6. ^ http://cardiaceps.org
  7. ^ http://www.jecgonline.com/content/edboard
  8. ^ http://content.onlinejacc.org/SS/JACCEditorialBoard.aspx
  9. ^ a b c http://www.uticaod.com/article/20101016/News/310169949
  10. ^ a b c http://www.mmrl.edu/history
  11. ^ a b c d http://www.mainlinehealth.org/wtn/Page.asp?PageID=WTN001687
  12. ^ http://newwestminstercollege.ca/professor-dr-charles-antzelevitch-b-a-ph-d/
  13. ^ Antzelevitch C (1977). Cardiac Actions of Quinidine (Thesis). Syracuse (NY): State University of New York Upstate Medical Center
  14. ^ a b http://circ.ahajournals.org/content/61/1/182.long
  15. ^ http://onlinelibrary.wiley.com/doi/10.1111/j.1540-8159.1982.tb00030.x/abstract
  16. ^ http://journals.lww.com/cardiovascularpharm/Abstract/1985/03000/The_Effects_of_Milrinone_on_Action_Potential.21.aspx
  17. ^ a b http://circ.ahajournals.org/content/98/18/1928.full
  18. ^ http://www.ncbi.nlm.nih.gov/pubmed/10716483
  19. ^ a b http://www.ncbi.nlm.nih.gov/pubmed/18362027
  20. ^ a b http://onlinelibrary.wiley.com/doi/10.1111/j.1540-8167.1998.tb01844.x/abstract
  21. ^ http://www.jecgonline.com/article/S0022-0736(00)80004-7/abstract
  22. ^ a b http://www.internationaljournalofcardiology.com/article/S0167-5273(13)02296-1/abstract
  23. ^ a b http://www.heartrhythmjournal.com/article/S1547-5271(09)01377-0/abstract
  24. ^ http://circ.ahajournals.org/content/107/18/2355.long
  25. ^ a b http://onlinelibrary.wiley.com/doi/10.1111/j.1540-8159.2006.00336.x/abstract
  26. ^ a b http://onlinelibrary.wiley.com/doi/10.1196/annals.1420.012/abstract
  27. ^ http://www.heartrhythmjournal.com/article/S1547-5271(12)00102-6/abstract
  28. ^ http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0040288
  29. ^ http://www.jmmc-online.com/article/S0022-2828(13)00095-3/pdf
  30. ^ http://www.nature.com/nm/journal/v14/n2/full/nm1684.html
  31. ^ http://cardiovascres.oxfordjournals.org/content/50/3/426.long
  32. ^ Antzelevitch C (2004). “Cellular basis for the repolarization waves of the ECG.” In: Malik M, Camm AJ, editors. Dynamic Electrocardiography. Elmsford (NY): Blackwell Futura. p. 291–300. ISBN 1405119608
  33. ^ Antzelevitch C (2002). “Cellular basis for J, T and U waves of the ECG”. In: Ovsyshcher IE, editor. New Developments in Cardiac Pacing and Electrophysiology. Armonk (NY): Futura, p. 1–8. ISBN 0879937068
  34. ^ http://cardiovascres.oxfordjournals.org/content/32/3/593.long
  35. ^ http://www.ncbi.nlm.nih.gov/pubmed/2826039
  36. ^ http://circres.ahajournals.org/content/69/6/1427.long
  37. ^ http://circres.ahajournals.org/content/68/6/1729.short
  38. ^ a b http://onlinelibrary.wiley.com/doi/10.1111/j.1540-8167.1999.tb00287.x/abstract
  39. ^ http://www.ncbi.nlm.nih.gov/pubmed/11099355
  40. ^ http://www.nejm.org/doi/full/10.1056/NEJMc0708182
  41. ^ http://www.ncbi.nlm.nih.gov/pubmed/18926326
  42. ^ http://www.nejm.org/doi/full/10.1056/NEJMoa071968
  43. ^ http://www.nejm.org/doi/full/10.1056/NEJMoa0907589
  44. ^ http://www.pubfacts.com/detail/21600720/The-early-repolarization-pattern-in-the-general-population-clinical-correlates-and-heritability
  45. ^ http://circ.ahajournals.org/content/98/18/1921.long
  46. ^ http://circ.ahajournals.org/content/100/15/1660.full
  47. ^ http://www.nejm.org/doi/full/10.1056/NEJM200007273430405
  48. ^ Antzelevitch C, Brugada P, Brugada J, Brugada R, Nademanee K, Towbin JA. The Brugada Syndrome. Armonk (NY): Futura Publishing; 1999. (Camm AJ, editor. Clinical approaches to tachyarrhythmias; vol. 10). ISBN: 0879934344.
  49. ^ http://circ.ahajournals.org/content/106/19/2514.full
  50. ^ http://circ.ahajournals.org/content/111/5/659.long
  51. ^ Antzelevitch C, Yan GX, Ackerman MJ, Borggrefe M, Corrado D, Guo J, Gussak I, Hasdemir C, Horie M, Huikuri H, Ma C, Morita H, Nam GB, Sacher F, Shimizu W, Viskin S, Wilde AA. J wave syndromes expert consensus conference: emerging concepts and gaps in knowledge. Soon to be In Press
  52. ^ http://circ.ahajournals.org/content/110/8/904.short
  53. ^ http://content.onlinejacc.org/article.aspx?articleID=1143752
  54. ^ https://scholar.google.com/citations?user=Wtry1CcAAAAJ&hl=en
  55. ^ https://professional.heart.org/professional/ResearchPrograms/ApplicationInformation/SupportingResources/UCM_320497_Affiliate-List-by-States.jsp

External Links

LIMR faculty page for Charles Antzelevitch
Prominent Cardiac Researcher, Charles Antzelevitch, PhD, Joins Lankenau Institute for Medical Research and Lankenau Heart Institute Template:Persondata DEFAULTSORT:Antzelevitch, Charles. Category:Living people Category:Cardiology Category:Electrophysiology Category:Pharmacology Category:American medical researchers

Retrieved from "https://en.wikipedia.org/w/index.php?title=Charles_Antzelevitch&oldid=714122383"